Please use this identifier to cite or link to this item:
https://www.arca.fiocruz.br/handle/icict/7947
VALIDATION AND UTILIZATION OF PCR FOR DIFFERENTIAL DIAGNOSIS AND PREVALENCE DETERMINATION OF ENTAMOEBA HISTOLYTICA/ENTAMOEBA DISPAR IN SALVADOR CITY, BRAZIL.
Entamebíase/diagnóstico
Entamebíase/parasitologia
Reação em Cadeia da Polimerase/métodos
Brasil/epidemiologia
DNA de Protozoário/análise
Diagnóstico Diferencial
Entamoeba/classificação
Entamoeba/isolamento & purificação
Entamoeba histolytica/genética
Entamoeba histolytica/isolamento & purificação
Entamebíase/epidemiologia
Fezes/parasitologia
Humanos
Prevalência
Sensibilidade e Especificidade
Affilliation
Fundação Oswaldo Cruz. Centro de Pesquisa Gonçalo Moniz. Health and Investigative Medicine Biotechnology . Salvador, BA, Brasil. Salvador, BA, Brasil
Universidade Federal da Bahia. Faculdade de Farmácia. Salvador, BA, Brasil / Fundação Oswaldo Cruz. Centro de Pesquisa Gonçalo Moniz. Laboratory of Pathology and Molecular Biology. Salvador, BA, Brasil
Universidade Federal da Bahia. Faculdade de Farmácia. Salvador, BA, Brasil
Universidade Federal da Bahia. Faculdade de Farmácia. Salvador, BA, Brasil / Fundação Oswaldo Cruz. Centro de Pesquisa Gonçalo Moniz. Laboratory of Pathology and Molecular Biology. Salvador, BA, Brasil
Universidade Federal da Bahia. Faculdade de Farmácia. Salvador, BA, Brasil
Abstract
Amoebiasis is an infection caused by Entamoeba histolytica and is a potential health risk in countries in which health barriers are inappropriate. Since the discovery of Entamoeba dispar, the prevalence of amoebiasis has been modified. OBJECTIVE: This study has standardized the PCR technique applied for the diagnosis of different species of the E. histolytica/E. dispar complex and has evaluated the prevalence of infection among patients attending private and public clinical laboratories in Salvador City, Bahia State, Brazil. RESULTS: Analysis of 52,704 stool samples by microscopic examination demonstrated that 1,788 (3.4%) were positive for the E. histolytica/E. dispar complex and infection occurred more often in samples originated from public clinical laboratories (5.0%) than those that came from private laboratories (3.2%). PCR performed in approximately 15% (262) E. histolytica/E. dispar complex positive samples, randomly chosen, amplified 227 samples (86.6%), all of them positive for E. dispar. The non-amplified 35 samples (13.4%) were also negative for E. histolytica-specific galactose adhesin. Moreover, to exclude a probable infection caused by E. hartmanni, morphometric analysis demonstrated that non-amplified samples had cyst sizes comparable to E. histolytica/E. dispar (>10 µm). CONCLUSION: The absence of amplification of these samples indicates the presence of PCR inhibitors in the stool samples or the presence of DNA from Entamoeba species other than E. dispar, E. histolytica or E. hartmanni.
DeCS
Entamoeba/genéticaEntamebíase/diagnóstico
Entamebíase/parasitologia
Reação em Cadeia da Polimerase/métodos
Brasil/epidemiologia
DNA de Protozoário/análise
Diagnóstico Diferencial
Entamoeba/classificação
Entamoeba/isolamento & purificação
Entamoeba histolytica/genética
Entamoeba histolytica/isolamento & purificação
Entamebíase/epidemiologia
Fezes/parasitologia
Humanos
Prevalência
Sensibilidade e Especificidade
Share